Bulbine frutescens Phytochemicals as a Promising Anti-cancer Drug Discovery Source: A Computational Study
Deregulated signaling pathways/processes result in uncontrolled cell proliferation and cell survival. Adaptation to this condition often resulted in chemotherapeutic resistance in cancer cells. According to the concept of various signaling involvement in the development of cancer, fractional inhibition of numerous targets can be more productive than single one. Bulbine frutescens is a traditional medicinal plant of South Africa, has been preliminarily reported for anti-proliferative and anti-drug resistance property in cancer cells. Anticancer and mode of action of various phytochemicals present in the plant not yet has been studied. The present in silico study was designed to assess the potential B. frutescens phytochemicals as novel natural inhibitors of signaling proteins involved in cancer. Furthermore, drug-likeness property, ADME/T (absorption, distribution, metabolism, excretion/toxicity) properties, interaction ability with xenobiotic enzymes and biological activities were predicted by using various computational tools. For the first time Palmidin C, AC1NSTKE, Bulbine-knipholone and 4′-Demethylknipholone 2′-β-D-glucopyranoside compounds have been reported for their anticancer potential. These phytochemicals have better potential to inhibit NFkB, TGF-β, PI3K, and JAK2 proteins than their respective standard inhibitors. Lead phytochemicals showed better ADME/T, drug-likeness, xenobiotic enzymes interactions and biological activities. In conclusion, Palmidin C, AC1NSTKE and Bulbine-knipholone are the novel potent anticancer phytochemicals and need to be studied further in vitro and in vivo.
KeywordsCancer Signaling pathway Natural inhibitors Bulbine frutescens
PPK and SK acknowledges financial support from UGC, India and Central University of Punjab Bathinda, Punjab, India for providing financial assistance in the form of UGC-CSIR Senior Research Fellowship and UGC-BSR Research Start-Up-Grant, [No.F.30-372/2017(BSR)] respectively.
Conflict of Interest
The authors declare that they have no conflict of interest.
- Dallakyan S. PyRx-python prescription v. 0.8. La Jolla: The Scripps Research Institute; 2010.Google Scholar
- Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Dis Dev. 2009;12:189–96.Google Scholar
- Lee SK, Lee IH, Kim HJ, Chang GS, Chung JE, No KT. The PreADME approach: web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties. EuroQSAR 2002 Designing Drugs and Crop Protectants: processes, problems and solutions. 2003. p. 418–20.Google Scholar
- Mouli KC, Vijaya T, Rao SD. Phytoresources as potential therapeutic agents for cancer treatment and prevention. J Global Pharma Tech. 2009;1:4–18.Google Scholar
- Pinar R. To investigate knowledge of Turkish people about cancer. Cancer Agenda. 1998;12:66–73.Google Scholar